|Bid||226.90 x 0|
|Ask||227.10 x 0|
|Day's Range||225.90 - 231.00|
|52 Week Range||166.50 - 245.50|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||22.27|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for SOBI.ST
Sobi North America, a unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure. The authorization of Sobi's Kineret adds another option for COVID treatment in the United States, as the disease moves from a pandemic to an endemic stage.
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.